GlaxoSmithKline's corporate venturing division SR One and Biogen Idec's $200m New Ventures unit alongside undisclosed other investors have bolstered iPierian's series B round.
Two more strategic investors have joined the extended series B round for US-based drug development company iPierian.
GlaxoSmithKline’s corporate venturing division SR One and Biogen Idec’s $200m New Ventures unit alongside undisclosed other investors added $6m to iPierian’s series B round.
The round has now closed at $28m, having raised $22m in July when Google Ventures, the corporate venturing division of search engine company Google, led the initial closing.
Rajeev Dadoo, a partner at SR One, will be a board…
